$AVR

L1 Capital Pty Ltd purchased $6.7M of AVR (indirect holdings)

L1 Capital Pty Ltd purchased 884,809 indirectly-held shares of Anteris Technologies Global Corp. (AVR) at an average of $7.58 ($7.51–$7.78, $6.71M total) across 2 trades over 2026-10-02 to 2026-10-05.

Original reporting
SEC EDGAR · L1 Capital Pty Ltd
Published Oct 6, 2026, 10:18 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 6, 2026, 10:47 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$AVR
Bullish
high confidence
Mentioned
$AVR
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AVRBullishLow
01

Why it matters

The $6.7M purchase by a 10% owner may be interpreted as a bullish signal, but the amount is modest relative to market cap.

02

Market read

New insider purchase provides fresh data for traders; impact likely limited to short‑term price support.

03

What to watch

Potential hidden risks in AVR's pipeline or market conditions that the insider may be aware of.

Relevance 7/10Novelty 6/10Timing: after-market today

Background

Form 4 filings disclose insider trades and are primary sources for new ownership changes.

Company-level read

Ticker impact

$AVRBullishHigh confidence
Context

SEC Form 4 shows L1 Capital Pty Ltd bought $6.7M of AVR shares, increasing its stake to 12.8M shares.

Expected impact

modest upside as traders price in insider confidence

Evidence & confidence

The purchase is a fresh, material insider transaction (10% owner) disclosed for the first time, indicating strong belief in the company's prospects.

Market effects

Limited; the transaction is company‑specific and does not affect the broader sector.

Minimal; only relevant to investors tracking AVR.

Low; no global macro implications.

Counterpoint

The purchase could be a routine portfolio rebalancing rather than a strong endorsement.

Key entities

  • L1 Capital Pty Ltd

    Purchaser and 10% owner of AVR.

  • Anteris Technologies Global Corp.

    Company whose shares were purchased.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AVRMedAI 8/10

Small Cap watch: ASX small caps ease after strong week as NewPeak, Orthocell and Anteris advance drilling, sales and data

The S&P/ASX Small Ordinaries Index fell 0.74% on Friday but gained 3.03% over the week. NewPeak Metals completed drilling in Argentina, Orthocell reported record US sales, and Anteris Technologies released positive heart valve data. NewPeak tested gold mineralization, Orthocell sold 92 units of Remplir, and Anteris' valve showed improved haemodynamics in 22 patients.

$AVRMedAI 8/10

Anteris Reports Medium-Size DurAVR THV Outcomes from the EMBARK Study at TCT 2026

Anteris Technologies (NASDAQ: AVR, ASX: AVR) reported 30-day outcomes for its DurAVR THV in 22 patients with medium aortic annuli, showing positive hemodynamic and safety results. The DurAVR THV is being evaluated in the ongoing PARADIGM trial, a global study comparing it to commercially available TAVRs. The company aims to confirm the valve's effectiveness in a randomized setting.

$AVRMedAI 8/10

Anteris Technologies secures German clearance to expand PARADIGM heart valve trial

Anteris Technologies (ASX:AVR, NASDAQ:AVR) received German regulatory approval to expand its PARADIGM heart valve trial, allowing patient recruitment in Europe's largest market. The trial aims to enroll 1,000 patients to evaluate the DurAVR valve against existing devices. The company expects Germany's expertise to accelerate enrollment. DurAVR is a transcatheter heart valve designed to mimic a healthy aortic valve.